ACTRN12613000766718尚未招募2 期
An randomised, double blind placebo controlled, parallel ascending multiple dose study to evaluate the tolerability of Honey Cyclopower (trademark) taken daily in healthy volunteers
Manuka Health NZ Ltd0 个研究点目标入组 64 人开始时间: 2013年7月9日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- All
入选标准
- •healthy volunteers
- •non-smoking
- •BMI 18-29kg/m2
- •using contraception if appropriate
- •able to communicate clearly with research staff and able to give informed consent
排除标准
- •medical history of significant disease or abnormality
- •use of prescription drugs 7 days prior to testing (except for oral contraceptive and analgesia)
- •use of recreational drugs in the 7 days prior to testing
- •known allergy or food intolerance to fibre based products
- •known allergy or intolerance of bee products or Honey Cyclopower
- •significant illness in the 2 weeks prior to testing
- •dosing of a study drug within the 30 days prior to testing
研究者
相似试验
已完成
2 期
ACCORD: Assessment of Carnitine for Clinical Outcomes in Renal DiseaseACTRN12609000024246niversity of South Australia60
进行中（未招募）
1 期
A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPD.Chronic obstructive pulmonary disease (COPD)MedDRA version: 18.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-004715-37-ESAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden269
进行中（未招募）
不适用
Safety and efficacy of empagliflozin in two different daily doses as add-on to metformin therapy in patients with type 2 diabetes mellitusType 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000905-53-LTBoehringer Ingelheim RCV GmbH & Co KG936
进行中（未招募）
不适用
A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy - ASCENDDiabetic NephropathyEUCTR2005-000604-14-FISpeedel Pharma Ltd.2,364
进行中（未招募）
不适用
A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPDEUCTR2014-004715-37-ITAstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden250